

See B3
AB
14. (Amended) Cosmetic prevention and/or treatment method according to Claim 1, characterized in that the composition also comprises at least one compound chosen from the group consisting of extract of *Sophora japonica*, methylsilaryl lactate, copper gluconate and zinc gluconate, and mixtures of these compounds.

15. (Amended) Use of a composition as defined in Claim 1, to prepare a dermatological medicinal product for preventing and/or treating skin stretchmarks.

REMARKS

Applicant respectfully requests that the foregoing amendments be made prior to examination of the present application.

Respectfully submitted,

Date April 5, 2001

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5571
Facsimile: (202) 672-5399

By *Philip J. Antinolo*
for / Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Reg. No.
38,819

MARKED UP VERSION OF AMENDED CLAIMS

3. Cosmetic prevention and/or treatment method according to Claim 1 [or 2], characterized in that the anti-stretchmark agent is chosen from the group consisting of the soya peptide Phytokine® and the tripeptide Kollaren-CPP®, and mixtures of these peptides.

4. Cosmetic prevention and/or treatment method according to [any one of Claims] Claim 1 [to 3], characterized in that the proportion of anti-stretchmark agent is between about 0.1% and about 10% by weight relative to the total weight of the composition.

5. Cosmetic prevention and/or treatment method according to [any one of Claims] Claim 1 [to 4], characterized in that the composition also comprises at least one a-hydroxy acid, in combination with the anti— stretchmark agent.

7. Cosmetic prevention and/or treatment method according to Claim 5 [or 6], characterized in that the proportion of a-hydroxy acid is between about 0.1% and about 20% by weight relative to the total weight of the composition.

8. Cosmetic prevention and/or treatment method according to [any one of the preceding claims] Claim 1, characterized in that the composition comprises an anti-stretchmark agent chosen from the group consisting of the soya peptide Phytokine® and the tripeptide Kollaren—CPP® and mixtures of these peptides, in combination with lactic acid.

9. Cosmetic prevention and/or treatment method according to [any one of the preceding claims] Claim 1, characterized in that the composition also comprises a compound for adjusting the pH to a value of between about 2 and about 4.

10. Cosmetic prevention and/or treatment method according to [any one of the preceding claims] Claim 1, characterized in that the composition also comprises at least one substance-P and neuropeptide-Y inhibitor compound.

12. Cosmetic prevention and/or treatment method according to Claim 10 [or 11], characterized in that the proportion of substance-P and neuropeptide-Y inhibitor compound

is between about 0.1 % and about 5 % by weight relative to the total weight of the composition.

13. Cosmetic prevention and/or treatment method according to [any one of the preceding claims] Claim 1, characterized in that the composition comprises an anti-stretchmark agent chosen from the group consisting of the soya peptide Phytokine® and the tripeptide Kollaren_CPP® and mixtures of these peptides, in combination with lactic acid and *Enteromorpha compressa*

14. Cosmetic prevention and/or treatment method according to [any one of the preceding claims] Claim 1, characterized in that the composition also comprises at least one compound chosen from the group consisting of extract of *Sophora japonica*, methylsilaryl lactate, copper gluconate and zinc gluconate, and mixtures of these compounds.

15. Use of a composition as defined in [any one of Claims] Claim 1 [to 14], to prepare a dermatological medicinal product for preventing and/or treating skin stretchmarks.

09806834-040501